USA-based Calgenex Corp has introduced Dermalleve, its new over-the-counter topical drug treatment for psoriasis, eczema and seborrheic dermatitis. The product combines maximum-strength anti-pruritic medicine with natural skin conditioners and emollients to stop the itching, reduce inflammation and support the body's healing process.
Dermalleve contains 1% hydrocortisone, the maximum strength OTC anti-pruritic allowed by the US Food and Drug Administration. According to Calgenex, what sets its product apart from other topical treatments is its patent-pending blend of natural ingredients, including alpha-hydroxy acids, skin-nourishing nutrients and skin conditioners such as aloe vera, shea butter, vitamin E, jojoba oil and silicone. This novel lotion base helps to "gently remove dead skin cells while skin-nourishing nutrients, conditioners and moisturizers support healthy skin. In fact, whereas other anti-itch creams use inexpensive petroleum as a base, Dermalleve is made with 75% cooling and moisturizing purified aloe vera juice," the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze